Leukaemia 1997,11(11):1833–1841.CrossRef 63. Fulda S, Los M, Friesen C, Debatin KM: Chemosensitivity of solid tumour cells in vitro is related to activation of the CD95 system. Int J Cancer 1998,76(1):105–114.PubMedCrossRef 64. Fulda S: Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol 2010, 2010:370835.PubMed 65. Reesink-Peters N, Hougardy BM, van den Heuvel FA, Ten Hoor KA, Hollema H, Boezen HM, de Vries EG, de Jong S, van der Zee AG: Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynaecol Oncol 2005,96(3):705–713.CrossRef 66. Rai KR, Moore J, Wu J, Novick SC, O’Brien SM: Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide

for replased/refractory chronic lymphocytic leukaemia (CLL) on survival in patients who achieve CR/nPR: Five-year follow-up from a randomized phase III study [abstract]. J Clin Selleckchem Anlotinib Oncol 2008, 26:7008. 67. Abou-Nassar K, Brown JR: Novel agents for the treatment of chronic lymphocytic leukaemia. Clin Adv Haematol Oncol 2010,8(12):886–895. 68. Kang MH, Reynolds CP, Bcl-2 inhibitors: A-1210477 cell line Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009, 15:1126–1132.PubMedCrossRef 69. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten

MJ, Nettesheim DG, buy IWR-1 Ng S, Nimmer PM, O’Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005,435(7042):677–681.PubMedCrossRef 70. Albershardt TC, Salerni BL, Soderquist RS, Bates DJ, Pletnev AA, Kisselev AF, Eastman A: Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing

Protein tyrosine phosphatase the endoplasmic reticulum stress response and upregulating BH3-only protein NOXA. J Biol Chem 2011,286(28):24882–24895.PubMedCrossRef 71. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C, Schuppan D: Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut 2005,54(9):1298–1308.PubMedCrossRef 72. Wu X, Liu X, Sengupta J, Bu Y, Yi F, Wang C, Shi Y, Zhu Y, Jiao Q, Song F: Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells. Indian J Exp Biol 2011,49(2):105–112.PubMed 73. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D: Retrovirus-mediated wild-type p53 gene transfer to tumuors of patients with lung cancer. Nature Medicine 1996,2(9):985–991.PubMedCrossRef 74. Chène P: p53 as a drug target in cancer therapy.